Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that physicians will increase their usage of both Abbott's Humira and Centocor/Schering-Plough/Tanabe Seiyaku's Remicade over the next two years. According to the new Treatment Algorithm report entitled Treatment Algorithms for Crohn's Disease, both primary care physicians and gastroenterologists project that they will double their first-line use of Remicade. Gastroenterologists also forecast an impressive increase in their use of Humira, from 9% for first- and second-line treatment combined in 2006 to 41% for both lines of therapy combined in 2008.

"Primary care physicians' use of Humira in early-line therapy is currently 44% according to their estimates; they expect the proportion to reach 56% in 2008," said Madhuri Borde, Ph.D., analyst at Decision Resources. "However, lack of FDA approval for Humira in Crohn's disease, coupled with its high price, makes the outlook for reimbursement currently very poor. These hurdles appear to be an overwhelming limitation for Humira at the moment, with 55% of primary care physicians and 69% of gastroenterologists citing these disadvantages."

The report also finds that Crohn's disease sufferers often need to visit the doctor numerous times before getting treatment. Within one year of initial diagnosis, 54.5% of patients with Crohn's disease did not receive a prescription drug therapy. Gastroenterologists and primary care physicians say that mild disease, patient refusal, and misdiagnosis or uncertain diagnosis are the primary culprits behind this low treatment rate.

"Surveyed gastroenterologists say they prefer to see a patient three to four times before feeling comfortable initiating Crohn's disease treatment, whereas primary care physicians need to see a patient an astonishing seven times," continued Dr. Borde.

Treatment Algorithms for Crohn's Disease allows pharmaceutical organizations to quantify lines of therapy through primary research and patient-level data. The report enables users to:

  * Understand current treatment patterns and anticipate future market     dynamics   * Drive product growth through accurate knowledge of a product's     positioning among the lines of therapy and why physicians use it at that     point   * Target specific competitors that are preceding or following a product     and benefit from actionable analysis of the path to treatment and     physicians' decision parameters   * Develop more sophisticated market-forecasting patient-flow models based     on the unique, accurate information regarding the percentage of patients     receiving a product at specific stages in the course of therapy    About Treatment Algorithm Insight Series 

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics® to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides:

  * Summary of U.S. medical practice based on interviews with leading     experts in the field   * Qualitative diagnosis/referral/treatment algorithm for the United States   * Drug usage by lines of therapy (1st, 2nd, 3rd line)   * Discussion of key freeform combinations by lines of therapy   * Product share (class and specific compound level) within each line of     therapy (1st, 2nd, 3rd line)   * Progression of therapy from key 1st line products   * Pathway to key therapies from previous therapies   * Qualitative analysis of 2-year forecast incorporating upcoming launches,     changes in reimbursement, etc.    About Decision Resources 

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Merck Purchases Sirna Therapeutics to Acquire RNA Interference Technology

View Now